This page is updated frequently with new Diabetes-related patent applications.
520+ Diabetes-related patent PDFs
| Computerized system, device, method and program product for medical treatment automation|
A computerized system and method that automates diagnosing and prescribing treatment plans for patients with medical conditions, such as: dermatological (e.g. Acne, dark spots, anti-aging), high blood pressure, diabetes, pre and post-surgical care, pain management, simple infections, and other medical conditions with standardized treatment protocols.
| Peptide agonists of glp-1 activity|
Novel peptide agonists of glp-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the glp-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable.
Zealand Pharma A/s
| Insulin dosage proposal system|
A device for proposing an insulin dosage for a diabetes patient, wherein the device comprises an input interface configured for receiving patient glucose level data indicative of glucose level information of the patient, a processor configured for determining the insulin dosage in an interactive time-dependent manner based on applying the received patient glucose level data to at least only predefined insulin dosage determining criterion, and an output interface configured for outputting a result of the determining as a proposal for the insulin dosage indicative of doses and assigned times of the day according to which insulin is to be administered to the diabetes patient.. .
Medizinische Universität Graz
| Treatment of immune disorders|
The present disclosure relates to stem cells which express high levels of angeopoetin-1 (ang1) and uses thereof in inhibiting m1-type macrophage production and treating inflammatory disease such as diabetes.. .
Mesoblast International Sarl
| Magnesium compositions and uses thereof for neurological disorders|
A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound.
| Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine|
Methods of treating patients suffering from non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash), including those also suffering front type ii diabetes mellitus (t2dm), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.. .
Hadasit Medical Research Services And Development Ltd.
| Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders|
Compounds and methods are provided for the treatment of, inter alia, type ii diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active..
Cymabay Therapeutics, Inc.
| Activation of amp-protein activated kinase by oxaloacetate compounds|
The present invention relates to oxaloacetate compounds that activate amp-activated protein kinase (ampk), including the preparation of the compounds, compositions containing the compounds, preserving said compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, obesity, cardiovascular disease, alzheimer's disease, and cancer.. .
| Method for suppressing diabetes and/or hepatic lipids using tormentic acid|
Provided is a method for suppressing diabetes and/or hepatic lipids in a mammal to lower blood glucose levels and hepatic total lipids and triacylglycerol contents by increasing amp-activated protein kinase (ampk) phosphorylation in both skeletal muscle and liver tissue, and akt phosphorylation and membraneprotein levels of glucose transporter 4 (glut4) in skeletal muscle. The method comprises administrating to the mammal an effective amount of tormentic acid or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier..
| Treatments for diabetes mellitus and obesity|
Methods of treatment in subjects suffering from diabetes mellitus or obesity are provided. The methods comprise ablation of a region of the small intestine in the subject, in particular ablation of a region of the duodenum.
Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans
Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kda and 70 kda, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity.
Tate & Lyle Ingredients France Sas
Glp-1/glucagon receptor co-agonists for medical use
The present invention relates to novel glucagon derivatives which are glp-1/glucagon receptor co-agonists, and to the use of said glucagon derivatives in medicine, such as in the treatment of diabetes, obesity and related diseases and conditions.. .
Novo Nordisk A/s
Modulating gamma-c-cytokine activity
Embodiments relate to peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Chimeric fibroblast growth factor 19 proteins and methods of use
The present invention relates to a chimeric protein that includes an n-terminus coupled to a c-terminus, where the n-terminus includes a portion of a paracrine fibroblast growth factor (“fgf”) and the c-terminus includes a c-terminal portion of an fgf 19 molecule. The portion of the paracrine fgf is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification.
New York University
Thienopyranones as kinase and epigenetic inhibitors
The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infection, atheroscleosis, type 1 or 2 diabetes, obesity, inflammatory disease, or myc-depenent disorder including by modulating biological processes by the inhibition of pi3 kinase and/or bromodomain protein binding to substrates comprising the administration of a compound(s) of formula i-ix (or pharmaceutically acceptable salts thereof) as defined herein.. .
Signalrx Pharmaceuticals, Inc.
Sweetness receptor antagonist
Wherein each symbol is described herein, are useful for the prophylaxis or treatment of metabolic syndrome, diabetes, obesity and the like.. .
Human antibodies to human tnf-like ligand 1a (tl1a)
A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human tnf-like ligand 1a (htl1a) is provided. The human anti-htl1a antibodies are useful in treating diseases or disorders associated with tl1a, such as inflammatory diseases or disorders, e.g., inflammatory bowel diseases, including ulcerative colitis and crohn's disease, rheumatoid arthritis, and the like; autoimmune diseases or disorders, such as multiple sclerosis, diabetes, and the like; and allergic reactions, such as asthma and allergic lung inflammation..
Regeneron Pharmaceuticals, Inc.
Peptide analogs for treating diseases and disorders
Provided herein are peptides, that in combination with metformin, are effective for the treatment of type i diabetes, type ii diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. The peptides are selected from sequences seq id no: 11, seq id no: 12, seq id no: 13, seq id no: 14, seq id no: 15, seq id no: 16, seq id no: 17, seq id no: 19, seq id no: 20, seq id no: 21, seq id no: 22, seq id no: 23, and seq id no: 24..
Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity, and related metabolic disorders
The present invention relates to chimeric proteins that include an n-terminus coupled to a c-terminus, where the n-terminus includes an n-terminal portion of fibroblast growth factor 21 (“fgf21”) and the c-terminus includes a c-terminal portion of fibroblast growth factor 19 (“fgf19”). The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, as well as methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, methods of treating a subject in need of increased fgf21-βklotho-fgf receptor complex formation, methods of causing increased fgf21 receptor agonist-βklotho-fgf receptor complex formation, and methods of screening for compounds with enhanced binding affinity for the βklotho-fgf receptor complex involving the use of chimeric proteins of the present invention..
New York University
Inhibition of gliadin peptides
Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided.
Alba Therapeutics Corporation
Novel activators of glucokinase
The present invention provides for novel compounds of formulas i and ii and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia.
Metabasis Therapeutics, Inc.
Nitroxides for use in treating or preventing diabetes and obesity
Pharmaceutical compositions are provided that are useful in treating diabetes. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of genes related to diabetes.
Mitos Pharmaceuticals, Inc.
Methods and apparatus to reduce the impact of user-entered data errors in diabetes management systems
Embodiments provide systems, methods, and apparatus for reducing the impact of user-entered data errors in a data management system (dms) such as for diabetes. Embodiments include storing user-entered data received from a user into a primary dms database; storing secondary data received from a source other than the user into a secondary tracking database; associating the secondary data with one or more events described by the user-entered data; cross-checking the user-entered data against the associated secondary data; evaluating user-entered data based on the cross-checking results; presenting for review evaluated user-entered data; treating user-entered data in the primary dms database based on review results; and determining a diabetes management plan based on the treated user-entered data.
Ascensia Diabetes Care Holdings Ag
Uses of mito-ob transgenic mice
The mito-ob obese mouse model overexpresses the mitochondrial protein prohibitin (phb). Mito-ob male mice develop insulin resistance in addition to obesity and they do not develop overt diabetes.
University Of Manitoba
Fibronectin based scaffold domain proteins that bind to myostatin
The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, copd, chronic kidney disease, heart failure, myocardial infarction, and fibrosis.
Bristol-myers Squibb Company
Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering zn-α2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as β adrenergin receptor agonists, β adrenergin receptor antagonists, and/or glycemic control agents.. .
Benzo-fused heterocyclic derivatives useful as agonists of gpr120
The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by gpr120. More particularly, the compounds of the present invention are agonists of gpr120, useful in the treatment of, such as for example, type ii diabetes mellitus..
Janssen Pharmaceutica Nv
Superior control of blood glucose in diabetes treatment
Methods related to the treatment of diabetes and improving the control of blood glucose levels are provided. In particular, methods are provided for effectively reducing postprandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration.
Use of overground part of hedychium coronarium koenig in reducing blood glucose; extracts and compositions of overground part of hedychium coronarium koenig and their uses
The present invention is related to the use of an overground part of hedychium coronarium koenig in lowering blood glucose, increasing insulin levels and treating and/or preventing diabetes without overly reducing blood glucose in a subject; i.e., not reducing blood glucose in a fasting subject. The present invention also relates to an extract and composition of the overground part of hedychium coronarium koenig and its use in lowering blood glucose, increasing insulin levels and treating and/or preventing diabetes..
Development Center For Biotechnology
Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria
The present invention relates to a pharmaceutical and food composition for treating, preventing, or alleviating a metabolic disease, containing, as an active ingredient, extracellular vesicles derived from akkermansia muciniphila. The composition of the present invention can be used as a pharmaceutical/food composition and the like for treating, preventing, or alleviating metabolic diseases, in particular metabolic diseases such as obesity, diabetes, hyperlipidemia, arteriosclerosis, and hypertension, occurring or exacerbated due to a high fat diet.
Md Healthcare Inc.
Methods of isolating distinct pancreatic cell types
Methods of isolating distinct specific cell types within mixed populations of cells. Methods of isolating specific cell types among pancreatic cells, particularly from human islets of langerhans.
Yeda Research And Development Co. Ltd.
Compositions and methods for treating type 1 and type 2 diabetes and related disorders
The invention features compositions comprising in vitro generated beta cells capable of glucose-stimulated insulin secretion, methods of inducing beta cell maturation from embryonic or induced pluripotent stem cell-derived beta-like cells, and methods of using in vitro generated beta cells for the treatment of type 1 diabetes, type 2 diabetes, or a related disorder.. .
Salk Institute For Biological Studies
Sodium glucose co-transporter inhibitors and methods of their use
Sulfanyl-tetrahydropyran-based compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment of diseases and disorders such as diabetes and obesity are disclosed.. .
Lexicon Pharmaceuticals, Inc.
Furo[3,4-b]pyran compounds and pharmaceutical uses
Furo[3,4-b]pyran compounds similar in chemical structure to the natural product known as tan-2483b and their use for treating cancer, osteoporosis, type 2 diabetes, or immune diseases.. .
Victoria Link Limited
Type 1 Diabetes
Human Embryonic Stem Cell
Embryonic Stem Cell
Follow us on Twitter
This listing is a sample listing of patent applications related to Diabetes for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Diabetes with additional patents listed. Browse our RSS directory or Search for other possible listings.